

Supplementary Information for

A Genome-Wide Association Study for Myopia and Refractive Error Identifies a Susceptibility Locus at 15q25

Figure 1. Ancestry of the TwinsUK Samples with respect to three HapMap Phase 2 Reference populations (CEU-Caucasian, YRI-African and CHB-Chinese).




Figure 2. Quantile-Quantile for association between all SNPs analyzed and spherical equivalent in the main cohorts used in this study: (a) TwinsUK, (b) 1958 BC, (c) RS-I, (d) RS-II, (e) RS-III, (f) ERF.




Figure 3. Linkage Disequilibrium calculated in terms of r^2 . Black squares show perfect LD whereas clearer shades of grey show progressively fading LD.





Figure 4. Plot of Association observed Genome-wide (a) and on Chromosome 15 (b) in the TwinsUK Cohort. . The red line denotes $p=e-07$ level of association significance. On chromosome 15, the main peak, pointed at by red arrows corresponds to the SNPs near the RASGRF1 gene. The second locus (blue arrow) corresponds to the SNPs nearer the GJD2 gene.

(a)



(b)




Figure 5a. Distribution of age at the moment of visit in the UK Twin Cohort. Each bar represents a category of 5 years; numbers of individual are shown by a label on top of each bar.




Figure 5b Each bar represents a range within 1 Diopter and the number of individuals within that interval is shown on top of the respective bar.




Table 1. Detailed results of association of SNPs in the associated region regressing over observed phenotypes in the TwinsUK cohort

SNP	Reference Allele	Second Allele	Freq. for Ref. Allele	Regression Coefficient	Standard Error	p-value	Genotyped or Imputed
rs8027411	T	G	0.52	-0.351	0.065	7.91E-08	Partly Imputed
rs11072826	A	G	0.52	-0.344	0.065	1.38E-07	Fully Imputed
rs17175798	C	T	0.52	-0.344	0.065	1.38E-07	Fully Imputed
rs8033963	T	C	0.519	-0.342	0.065	1.59E-07	Partly Imputed
rs12439908	C	T	0.519	-0.342	0.065	1.69E-07	Fully Imputed
rs11629665	A	G	0.519	-0.342	0.065	1.69E-07	Fully Imputed
rs8031019	G	A	0.519	-0.342	0.065	1.69E-07	Fully Imputed
rs8031504	T	G	0.519	-0.342	0.065	1.69E-07	Fully Imputed
rs939658	G	A	0.52	-0.34	0.065	2.09E-07	Fully Imputed
rs939661	A	G	0.525	-0.332	0.065	2.73E-07	Genotyped
rs4778924	T	C	0.524	-0.329	0.064	3.34E-07	Fully Imputed
rs11631411	C	T	0.524	-0.329	0.064	3.34E-07	Fully Imputed
rs1915726	C	G	0.525	-0.329	0.065	3.69E-07	Fully Imputed
rs12902831	G	A	0.525	-0.328	0.065	3.82E-07	Fully Imputed
rs11630571	C	A	0.525	-0.328	0.065	3.82E-07	Fully Imputed
rs11635757	T	C	0.525	-0.328	0.065	3.83E-07	Fully Imputed
rs11634679	T	C	0.525	-0.328	0.065	3.83E-07	Fully Imputed
rs8024813	A	G	0.525	-0.327	0.065	3.93E-07	Fully Imputed
rs11634903	A	G	0.524	-0.327	0.065	3.94E-07	Fully Imputed
rs11638625	T	G	0.524	-0.327	0.065	3.96E-07	Fully Imputed
rs8031638	C	T	0.578	-0.331	0.066	4.48E-07	Partly Imputed
rs4778651	G	A	0.523	-0.318	0.065	9.81E-07	Genotyped
rs2204069	G	A	0.523	-0.318	0.065	1.00E-06	Fully Imputed
rs12903747	C	A	0.523	-0.318	0.065	1.01E-06	Fully Imputed
rs11634726	G	A	0.574	0.312	0.066	2.21E-06	Partly Imputed
rs11072829	G	A	0.575	0.311	0.066	2.49E-06	Fully Imputed
rs1434459	C	T	0.575	0.311	0.066	2.49E-06	Fully Imputed
rs8024572	A	G	0.575	0.309	0.066	2.67E-06	Genotyped
rs1474256	C	T	0.575	0.311	0.066	2.77E-06	Fully Imputed
rs8038464	T	A	0.586	0.305	0.068	6.35E-06	Fully Imputed
rs12595749	A	G	0.569	0.293	0.065	6.39E-06	Partly Imputed
rs2102999	T	C	0.512	0.276	0.065	1.95E-05	Genotyped
rs8035606	C	T	0.518	-0.355	0.083	2.06E-05	Partly Imputed
rs2049176	A	C	0.586	0.278	0.066	2.54E-05	Fully Imputed
rs6495367	G	A	0.583	0.27	0.066	3.86E-05	Genotyped
rs13380104	C	T	0.584	0.275	0.067	4.42E-05	Fully Imputed
rs1560895	C	T	0.585	0.346	0.085	4.52E-05	Partly Imputed
rs1007365	T	G	0.584	0.274	0.067	4.77E-05	Fully Imputed

Table 2. Transcription Factor Binding sites that are altered by the SNPs in the RASGRF1 promoter associated region .

	Ancestral Allele	Derived Allele
rs6495366 C/T	TF	TF
		V\$CREL.01
		V\$IK2.01
rs13380104 C/T		V\$CEBP.02
	V\$ZFX.01	V\$TCF11MAFG.01
	V\$AIRE.01	V\$ESRRB.01
	V\$NFY.02	V\$MEIS1A_HOXA9.01
		V\$AIRE.01
rs2049176 A/C		V\$PBX1_MEIS1.02
	V\$CMYB.01	V\$HOXC8.01
rs2102999 T/C	V\$HOX_PBX.01	V\$VMYB.05
	V\$HBP1.01	
	V\$NANOG.01	
	V\$HNF6.01	
rs8031638 C/T	V\$REV-ERBA.03	
	V\$GATA1.06	
rs8024813 A/G	V\$EVI1.05	
	V\$SSL1.01	
	V\$DELTAEF1.01	V\$NBRE.01
rs939661 A/G	V\$DEC1.01	V\$PTF1.01
	V\$MIT.01	
	V\$SREBP.03	
	V\$TR2.01	
	V\$RORA.01	
	V\$NBRE.01	
	V\$ESRRB.01	
	V\$PPAR_RXR.01	
	V\$RAR_RXR.01	
	rs4778651 A/G	
		V\$SIX4.01
rs8033963 C/T	V\$SRF.01	O\$VTATA.01
	V\$OCT1.01	V\$BRN5.02
	V\$DBP.01	V\$BRN2.01
	V\$OCT3_4.02	
	V\$FHXB.01	
	V\$GSH1.01	V\$XFD2.01
	V\$BRN3.03	
	O\$PTATA.01	
	V\$GSH1.01	

Table 3. Comparison in eye growth parameters between Wild Type and RASGRF1 Knock-Out mice

Observation Number	Sex	Body Weight (g)	Average Eye Weight (g)	Cross Dimension (mm)	Longitudinal Dimension (mm)	Average Crystalline Weight (mg)	Wild Type or Knockout
1	F	22.2	20	1.54	1.55	8.45	WT
2	F	23.08	20	1.58	1.61	7.45	WT
3	F	22.51	21	1.62	1.61	8.1	WT
4	M	27.55	20	1.64	1.62	7.25	WT
5	M	28.32	20.5	1.61	1.57	7.7	WT
6	M	29.46	20.5	1.52	1.61	7	WT
7	M	28.93	21	1.64	1.66	6.9	WT
8	F	20.98	20	1.63	1.6	8.35	KO
9	F	24.06	21.5	1.59	1.63	8.2	KO
10	F	20.73	19.5	1.6	1.57	8.45	KO
11	F	23.53	21	1.6	1.6	7.95	KO
12	F	23.37	21	1.67	1.61	7.75	KO
13	M	13.97	20	1.57	1.55	8.45	KO
14	M	29.04	19	1.55	1.59	7.85	KO
15	F	21.47	20	1.62	1.6	7	WT
16	F	21.74	20	1.6	1.61	6.95	WT
17	M	28.2	21	1.63	1.63	6.8	WT
18	M	30.45	20.5	1.62	1.64	7.25	WT
19	M	28.19	21	1.67	1.67	7.1	WT
20	M	25.98	21	---	---	6.8	WT
21	F	22.39	20	1.6	1.6	6.6	WT
22	M	26.04	20.5	1.6	1.61	7.05	WT
23	M	25.72	20	1.64	1.6	6.3	WT
24	M	26.14	21	1.64	1.66	6.65	WT
25	M	28.86	22	1.62	1.64	6.9	WT
26	M	28.99	21	1.62	1.63	6.65	WT
27	F	21.6	21	1.6	1.61	7.65	KO
28	F	21.69	21	1.62	1.65	7.4	KO
29	M	33.42	21.5	1.63	1.65	7.3	KO
30	M	23.76	20.5	1.59	1.62	7.35	KO
31	M	30.16	19.5	1.52	1.55	7.6	KO
32	F	26.2	19.5	1.55	1.6	7.55	KO
33	M	30.54	21	1.63	1.6	6.8	KO
34	M	33.11	21.5	1.62	1.65	7.2	KO
35	M	33.1	19.5	1.58	1.58	7.55	KO

Supplementary Note

In addition to the Acknowledgements in the main manuscript:

TDS is an NIHR senior Investigator and CJH an NIHR Senior Research Fellow. Genotyping of TwinsUK samples: We thank our laboratory staff led by Gabriela Surdulescu, the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, quality control and genotyping led by Leena Peltonen and Panos Deloukas; Le Centre National de Génotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by Aarno Palotie. Genotyping was also performed by CIDR as part of an NEI/NIH project grant, and we are grateful to Dr. Camilla Day and staff there.

The Rotterdam Study's funding for this work came from the Netherlands Organisation of Scientific Research (NWO); Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII); the Municipality of Rotterdam; the Netherlands Genomics Initiative (NGI); Center for Medical Systems Biology (CMSB) of NGI; Lijf en Leven, Krimpen a/d Lek; MD Fonds, Utrecht; de Henkes Stichting, Rotterdam; Oogfonds Nederland, Utrecht; Stichting Nederlands Oogheelkundig Onderzoek, Nijmegen/Rotterdam; Swart van Essen, Rotterdam; Bevordering van Volkskracht, Rotterdam; Blindenhulp, The Hague; Landelijke Stichting voor Blinden en Slechtienden (LSBS), Utrecht; Rotterdamse Vereniging voor Blindenbelangen, Rotterdam; OOG, The Hague; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn; The Rotterdam Eye Hospital Research Foundation (Stichting Wetenschappelijk Onderzoek Het Oogziekenhuis [SWOO] Prof. Dr. H.J. Flieringa, Rotterdam); Laméris Ootech BV, Nieuwegein; Topcon Europe BV, Capelle aan de IJssel, all in the Netherlands; and Heidelberg Engineering, Dossenheim, Germany. The authors are grateful to the study participants, the staff from the Rotterdam and ERF Study, and the participating general practitioners.

Genotyping for part of the Australian sample was funded by an NHMRC Medical Genomics Grant. Genotyping for the remainder was performed by CIDR as part of an NEI/NIH project grant, and we are grateful to Dr Camilla Day and staff. The Australian genotyping data were generated and processed by Grant W. Montgomery, Scott D. Gordon, Dale R. Nyholt, Sarah E. Medland, Brian P. McEvoy, Margaret J. Wright, Anjali K. Henders, Megan J. Campbell. SM is supported by an Australian NHMRC Career Development Award. We would additionally like to thank Jane MacKinnon, Shayne Brown, Lisa Kearns, Jonathan Ruddle, Paul Sanfilippo, Sandra Staffieri, Olivia Bigault, Colleen Wilkinson, Jamie Craig, Yaling Ma and Julie Barbour for assisting with clinical examinations. DAM is a Pfizer Australia Senior Research Fellow.

The 1958 British birth cohort is grateful to the Medical Research Council for the Health of the Public Grant for the biomedical assessment, including autorefraction data collection.